Literature DB >> 22981363

Effects of amino acid substitutions at positions 33 and 37 on UDP-glucuronosyltransferase 1A9 (UGT1A9) activity and substrate selectivity.

Porntipa Korprasertthaworn1, Andrew Rowland, Benjamin C Lewis, Peter I Mackenzie, Krongtong Yoovathaworn, John O Miners.   

Abstract

UGT1A9 contributes to the glucuronidation of numerous drugs and xenobiotics. There is evidence to suggest that the Met33Thr substitution, as occurs in the polymorphic variant UGT1A9*3, variably affects xenobiotic glucuronidation. The equivalent position in UGT1A4 is also known to influence enzyme activity, whilst an N-terminal domain histidine (His37 in UGT1A9) is believed to function as the catalytic base in most UGT enzymes. To elucidate the roles of key amino acids and characterise structure-function relationships, we determined the effects of amino acid substitutions at positions 33 and 37 of UGT1A9 on the kinetics of 4-methylumbelliferone (4-MU), mycophenolic acid (MPA), propofol (PRO), sulfinpyrazone (SFZ), frusemide (FSM), (S)-naproxen (NAP) and retigabine (RTB) glucuronidation, compounds that undergo glucuronidation at either a phenolic (4-MU, MPA, PRO), carboxylate (FSM, NAP), acidic carbon (SFZ) or amine (RTB) function. Substitution of Met33 with Val, Ile, Thr, and Gln, as occur in UGT1A1, UGT1A3, UGT1A4 and UGT1A6 respectively, variably affected kinetics and catalytic efficiency. Whilst K(m) values were generally higher and V(max) and CL(int) values were generally lower than for wild-type UGT1A9 with most substrate-mutant pairs, the pattern and the magnitude of the changes in each parameter differed substantially. Moreover, exceptions occurred; CL(int) values for MPA and FSM glucuronidation by the position-33 mutants were the same as or higher than that of UGT1A9. Mutation of His37 abolished activity towards all substrates, except RTB N-glucuronidation. The data confirm the importance of single amino acids for UGT enzyme activity and substrate selectivity, and support a pivotal role for residue-33 in facilitating substrate binding to UGT1A9. Crown
Copyright © 2012. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22981363     DOI: 10.1016/j.bcp.2012.08.026

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  9 in total

1.  Functional characterization of cynomolgus monkey UDP-glucuronosyltransferase 1A9.

Authors:  Kohei Yamamoto; Marina Mukai; Kenjiro Nagaoka; Keiko Hayashi; Hiroyuki Hichiya; Kenji Okada; Mikio Murata; Masato Shigeyama; Shizuo Narimatsu; Nobumitsu Hanioka
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2014-01-28       Impact factor: 2.441

Review 2.  PharmGKB summary: uric acid-lowering drugs pathway, pharmacodynamics.

Authors:  Ellen M McDonagh; Caroline F Thorn; John T Callaghan; Russ B Altman; Teri E Klein
Journal:  Pharmacogenet Genomics       Date:  2014-09       Impact factor: 2.089

3.  The effect of UGT1A and UGT2B polymorphisms on colorectal cancer risk: haplotype associations and gene–environment interactions.

Authors:  Andrea Y Angstadt; Terryl J Hartman; Samuel M Lesko; Joshua E Muscat; Junjia Zhu; Carla J Gallagher; Philip Lazarus
Journal:  Genes Chromosomes Cancer       Date:  2014-06       Impact factor: 5.006

4.  Longrange PCR-based next-generation sequencing in pharmacokinetics and pharmacodynamics study of propofol among patients under general anaesthesia.

Authors:  Oliwia Zakerska-Banaszak; Marzena Skrzypczak-Zielinska; Barbara Tamowicz; Adam Mikstacki; Michal Walczak; Michal Prendecki; Jolanta Dorszewska; Agnieszka Pollak; Urszula Lechowicz; Monika Oldak; Kinga Huminska-Lisowska; Marta Molinska-Glura; Marlena Szalata; Ryszard Slomski
Journal:  Sci Rep       Date:  2017-11-13       Impact factor: 4.379

5.  The effect of UGT1A9, CYP2B6 and CYP2C9 genes polymorphism on individual differences in propofol pharmacokinetics among Polish patients undergoing general anaesthesia.

Authors:  Adam Mikstacki; Oliwia Zakerska-Banaszak; Marzena Skrzypczak-Zielinska; Barbara Tamowicz; Michał Prendecki; Jolanta Dorszewska; Marta Molinska-Glura; Malgorzata Waszak; Ryszard Slomski
Journal:  J Appl Genet       Date:  2016-11-08       Impact factor: 3.240

6.  UDP-glycosyltransferase genes and their association and mutations associated with pyrethroid resistance in Anopheles sinensis (Diptera: Culicidae).

Authors:  Yong Zhou; Wen-Bo Fu; Feng-Ling Si; Zhen-Tian Yan; Yu-Juan Zhang; Qi-Yi He; Bin Chen
Journal:  Malar J       Date:  2019-03-07       Impact factor: 2.979

7.  The Effect of UGT1A9, CYP2B6 and CYP2C9 Genes Polymorphism on Propofol Pharmacokinetics in Children.

Authors:  Dimitrije Pavlovic; Ivana Budic; Tatjana Jevtovic Stoimenov; Dragana Stokanovic; Vesna Marjanovic; Marija Stevic; Milan Slavkovic; Dusica Simic
Journal:  Pharmgenomics Pers Med       Date:  2020-01-17

8.  Dimerization of human uridine diphosphate glucuronosyltransferase allozymes 1A1 and 1A9 alters their quercetin glucuronidation activities.

Authors:  Yan-Qing Liu; Ling-Min Yuan; Zhang-Zhao Gao; Yong-Sheng Xiao; Hong-Ying Sun; Lu-Shan Yu; Su Zeng
Journal:  Sci Rep       Date:  2016-03-30       Impact factor: 4.379

9.  Influence of uridine diphosphate-glucuronosyltransferases (1A9) polymorphisms on mycophenolic acid pharmacokinetics in patients with renal transplant.

Authors:  H S Ciftci; E Demir; M S Karadeniz; T Tefik; I Nane; F S Oguz; F Aydin; A Turkmen
Journal:  Ren Fail       Date:  2018-11       Impact factor: 2.606

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.